Novel fluoroimmunoassay for ovarian cancer biomarker CA-125
Cancer antigen 125 (CA-125) is a glycoprotein biomarker that denotes the presence of ovarian and reproductive cancers in women, with serum concentrations of CA-125 greater than 35 U/ml considered indicative of potential malignancies. A fluorescent immunoassay recently developed in our laboratory employing the ALYGNSA antibody-orientation system has been used to measure CA-125 levels. This system displayed significantly increased sensitivity with a detection limit of 1.5 U/ml compared to that of a commercial CA-125 enzyme-linked immunosorbent assay (15 U/ml) This tenfold lower level of detection of the ALYGNSA CA-125 assay should permit better identification and monitoring of ovarian cancer.
KeywordsFluoroimmunoassay ELISA Cancer biomarker CA-125
This work was supported by NSF grant # EEC-0425826 and a University of Massachusetts System-Wide CVIP award (MJM). One of us (DS) participated in the NSF Research Experience for Undergraduates (REU). Special thanks to Sinang Chourb and Brian Mackness for their useful discussions.
- 3.American Cancer Society (2007) Atlanta: American Cancer SocietyGoogle Scholar
- 8.Clarizia LJA (2006) Ph.D. Thesis University of Massachusetts, Lowell MassachusettsGoogle Scholar
- 9.Clarizia LJA, Sok D, Wei M, Mead J, Barry C, McDonald MJ (2009) Anal Bioanal Chemistry (in press)Google Scholar